STCube, Inc. (KOSDAQ:052020)

Market Cap	449.04B
Revenue (ttm)	11.30B
Net Income (ttm)	-21.44B
Shares Out	67.93M
EPS (ttm)	-439.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	163,092
Average Volume	207,610
Open	6,590.00
Previous Close	6,690.00
Day's Range	6,410.00 - 6,730.00
52-Week Range	3,940.00 - 10,470.00
Beta	-0.13
RSI	31.32
Earnings Date	Mar 21, 2025

About STCube

STCube, Inc., a biopharmaceutical company, develops medicines in South Korea. The company develops anti-cancer immunotherapeutic drugs and anti-viral drugs. It offers platform technologies, which include In vivo RNAi ICP target discovery platform for exploring material ICP target; glycosylation-specific antibody development platform for development of antibodies that mask glycosylation sites on target proteins; and ICP functional assay platform for development of various in vivo/in vitro analytical/experimental methods. The company’s product pi...

• Industry: Electronic Parts and Equipment, not elsewhere classified
• Founded: 1989
• Employees: 17
• Stock Exchange: KOSDAQ
• Ticker Symbol: 052020

Financial Performance

In 2024, STCube's revenue was 11.30 billion, an increase of 93.88% compared to the previous year's 5.83 billion. Losses were -21.44 billion, -12.50% less than in 2023.